- Home
- PKE vs ATAI Comparison
PKE vs ATAI Comparison
Compare PKE & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PKE
- ATAI
- Stock Information
- Founded
- PKE 1954
- ATAI 2018
- Country
- PKE United States
- ATAI Germany
- Employees
- PKE N/A
- ATAI N/A
- Industry
- PKE Military/Government/Technical
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- PKE Industrials
- ATAI Health Care
- Exchange
- PKE Nasdaq
- ATAI Nasdaq
- Market Cap
- PKE 260.2M
- ATAI 282.6M
- IPO Year
- PKE N/A
- ATAI 2021
- Fundamental
- Price
- PKE $13.65
- ATAI $2.31
- Analyst Decision
- PKE
- ATAI Strong Buy
- Analyst Count
- PKE 0
- ATAI 3
- Target Price
- PKE N/A
- ATAI $10.50
- AVG Volume (30 Days)
- PKE 44.8K
- ATAI 2.2M
- Earning Date
- PKE 05-15-2025
- ATAI 05-14-2025
- Dividend Yield
- PKE 3.66%
- ATAI N/A
- EPS Growth
- PKE N/A
- ATAI N/A
- EPS
- PKE 0.29
- ATAI N/A
- Revenue
- PKE $62,026,000.00
- ATAI $1,863,000.00
- Revenue This Year
- PKE N/A
- ATAI $242.21
- Revenue Next Year
- PKE N/A
- ATAI N/A
- P/E Ratio
- PKE $47.07
- ATAI N/A
- Revenue Growth
- PKE 10.75
- ATAI 572.56
- 52 Week Low
- PKE $11.96
- ATAI $1.03
- 52 Week High
- PKE $15.57
- ATAI $2.57
- Technical
- Relative Strength Index (RSI)
- PKE 51.88
- ATAI 76.68
- Support Level
- PKE $13.51
- ATAI $1.38
- Resistance Level
- PKE $14.09
- ATAI $2.38
- Average True Range (ATR)
- PKE 0.54
- ATAI 0.18
- MACD
- PKE -0.00
- ATAI 0.07
- Stochastic Oscillator
- PKE 62.45
- ATAI 93.03
About PKE Park Aerospace Corp.
Park Aerospace Corp designs develop and manufactures engineered, advanced composite materials and composite structures and assemblies and low-volume tooling for the aerospace markets and prototype tooling for such structures and assemblies. Geographically, the company derives a majority of revenue from North America and also has a presence in a company operates its business in Asia and Europe. It offers advanced composite Prepregs for Aircraft Structures and Interiors, Sigma Strut and Alpha Strut.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.